2245952-60-5
Chemical Structure
EGX358
- CAS No.: 2245952-60-5
- Formula:C13H18O2
- Molecular Weight:206.28
InChIKey: MUGVHYZIUXNFTE-XYPYZODXSA-N
SMILES: OC[C@@H]1CC[C@@H](C2=CC=C(C=C2)O)CC1
Biological Activity: EGX358 is a selective, orally active estrogen receptor β (ERβ) agonist with an EC50 of 27.4 nM for ERβ. EGX358 enhances object recognition ability, spatial memory and memory consolidation, and attenuates drug-induced vasomotor responses. EGX358 alleviates partial uterine atrophy without inducing uterine hypertrophy, while it does not alter anxiety-like behavior, depression-like behavior or body weight. EGX358 can be used in research related to Alzheimer's disease and menopause[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
EGX358 | EGX358 is a selective, orally active estrogen receptor β (ERβ) agonist with an EC50 of 27.4 nM for ERβ. EGX358 enhances object recognition ability, spatial memory and memory consolidation, and attenuates drug-induced vasomotor responses. EGX358 alleviates partial uterine atrophy without inducing uterine hypertrophy, while it does not alter anxiety-like behavior, depression-like behavior or body weight. EGX358 can be used in research related to Alzheimer's disease and menopause. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Schwabe MR, et al. The novel estrogen receptor beta agonist EGX358 and genotype influence memory, vasomotor, and anxiety outcomes in an Alzheimer's mouse model. Frontiers in aging neuroscience. 2024;16:1477045. [Content Brief]
- [2]. Fleischer AW, et al. Long-term oral administration of a novel estrogen receptor beta agonist enhances memory and alleviates drug-induced vasodilation in young ovariectomized mice. Hormones and behavior. 2021 Apr;130:104948. [Content Brief]
- [3]. Fleischer AW. Behavioral, Physiological, and Molecular Characterization of Long-Term Administration of a Novel Estrogen Receptor Beta Agonist in a Mouse Model of Menopause. Master’s thesis. University of Wisconsin-Milwaukee. 2021.
- [4]. Fleischer AW, et al. Effects of long-term oral treatment with a novel estrogen receptor beta agonist on memory, vasomotor, and anxiety outcomes in an EFAD mouse model of Alzheimer’s disease. Alzheimer’s & Dementia. 2023;19(Suppl 7):e065607.
